Phase 3 N=744 Ginger in Treating Nausea in Patients Receiving Chemotherapy for Cancer
Nausea · Vomiting
Primary: Change From Baseline of Peak Acute Nausea — 0.03; -0.56; -0.44; -0.15 units on a scale — p=.017
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=281 A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma
Multiple Myeloma
Primary: Maximum Severity of Oral Mucositis (World Health Organization (WHO) Grades 0/1, 2, 3, or 4) — 79; 36; 68; 26 Participants — p=0.188
Phase 1 N=38 Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies
Hodgkin's Disease · Non-Hodgkin's Lymphoma
Primary: The Maximum Tolerated Dose (MTD) of Niacinamide in the Combination of Vorinostat and Niacinamide — 100 mg/kg
Phase 3 N=486 HALT Progression of Polycystic Kidney Disease Study B
Kidney, Polycystic
Primary: Number of Participants With 50% Reduction of Baseline eGFR, End Stage Renal Disease (ESRD, Initiation of Dialysis or Preemptive Transplant), or Death. — 116; 115…
Phase 4 N=44 Efficacy and Safety of Temazepam in HIV Seropositive Patients With Insomnia
Insomnia
Primary: Mean Change in the Insomnia Severity Index — -4.01; 0.72 units on a scale
Phase 2 N=16 Efficacy of NOV-002 in Combination With Carboplatin in Chemotherapy-resistant Ovarian Cancer
Ovarian Cancer
Primary: Response Rate — 0; 1; 8; 6 Participants
N/A N=70 Study of Dopamine Versus Vasopressin for Treatment of Low Blood Pressure in Low Birth Weight Infants
Hypotension
Primary: Number of Subjects in Each Group Who Have Achieved an Optimal Mean Blood Pressure Value at 24 Hours of Life — 9; 9 participants
Phase 3 N=294 RenalGuard System and Contrast Media
Chronic Kidney Disease
Primary: Number of Participants With Contrast-induced Acute Kidney Injury — 146; 146 participants
Phase 4 N=17 Effect of Omega-3 Fatty Acid on Vitamin D Activation
Hemodialysis Patients · Vitamin D Insufficiency · Vitamin D Deficiency
Primary: 25-hydroxyvitamin D Levels at 12 Weeks — 44.4; 48.9 ng/ml
Phase 2 N=79 Oral CF101 Tablets Treatment in Patients With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Number of Subjects Achieving an American College of Rheumatology 20 (ACR20) Response (20% Improvement) — 18; 8 Participants — p=0.0352
Phase 2 N=253 Oral CF101 Tablets and Methotrexate Treatment in Rheumatoid Arthritis Patients
Rheumatoid Arthritis
Primary: ACR20 at Week 12 — 29; 34; 33 participants
N/A N=114 Comparison of Couple-Based PTSD Treatment and Couple-Based PTSD Education
Stress Disorders, Post-Traumatic
Primary: Psychological Functioning — 82.93; 82.93; 60.84; 60.81 units on a scale — p=<0.0001
N/A N=40 Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01)
HIV Infections
Primary: The Primary Outcome of This Study is the Proportion of Patients Having Detectable HIV-1 RNA Using the Single Copy Assay After 48 Weeks of Treatment and the Study…
Phase 3 N=322 Extension Study of Asenapine [P06107 (NCT01244815)] for Pediatric Bipolar Disorder (P05898)
Bipolar Disorder
Primary: Number of Participants Who Experienced Clinical or Laboratory Adverse Events — 197; 74 Participants
Phase 1 N=16 Safety Study of Transvenous Limb Perfusion in Human Muscular Dystrophy
Muscular Dystrophies · Duchenne Muscular Dystrophy · Becker Muscular Dystrophy
Primary: Muscle, Nerve, or Vascular Damage — 16 participants